A detailed history of Fmr LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 3,299,790 shares of APLS stock, worth $94.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,299,790
Previous 2,178,742 51.45%
Holding current value
$94.8 Million
Previous $128 Million 1.16%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$38.07 - $59.71 $42.7 Million - $66.9 Million
1,121,048 Added 51.45%
3,299,790 $127 Million
Q1 2024

May 13, 2024

BUY
$55.39 - $72.47 $4.78 Million - $6.25 Million
86,278 Added 4.12%
2,178,742 $128 Million
Q4 2023

Feb 13, 2024

SELL
$37.14 - $64.82 $6.21 Million - $10.8 Million
-167,302 Reduced 7.4%
2,092,464 $125 Million
Q3 2023

Nov 13, 2023

SELL
$23.65 - $89.22 $46.5 Million - $175 Million
-1,965,829 Reduced 46.52%
2,259,766 $86 Million
Q2 2023

Aug 11, 2023

BUY
$76.68 - $93.31 $161 Million - $196 Million
2,100,158 Added 98.81%
4,225,595 $385 Million
Q1 2023

May 11, 2023

BUY
$46.59 - $66.96 $31 Million - $44.5 Million
665,274 Added 45.56%
2,125,437 $140 Million
Q4 2022

Feb 13, 2023

SELL
$43.24 - $61.04 $43 - $61
-1 Reduced -0.0%
1,460,163 $75.5 Million
Q3 2022

Nov 10, 2022

BUY
$44.76 - $69.66 $3.21 Million - $5 Million
71,737 Added 5.17%
1,460,164 $99.7 Million
Q2 2022

Aug 12, 2022

SELL
$35.07 - $59.21 $321,416 - $542,659
-9,165 Reduced 0.66%
1,388,427 $62.8 Million
Q1 2022

May 13, 2022

SELL
$35.46 - $54.12 $7.7 Million - $11.8 Million
-217,267 Reduced 13.45%
1,397,592 $71 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $4.51 Million - $10 Million
143,694 Added 9.77%
1,614,859 $53.2 Million
Q2 2021

Aug 13, 2021

BUY
$40.9 - $64.9 $60.2 Million - $95.5 Million
1,471,165 New
1,471,165 $93 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.16B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.